How I treat ALK-positive non-small cell lung cancer

Since the discovery of anaplastic lymphocyte kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) and subsequent development of increasingly effective and central nervous system (CNS)-penetrant first-generation, second-generation and third-generation ALK tyrosine kinase inhibitors (TKIs)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:ESMO Open
Autors principals: McCusker, Michael G, Russo, Alessandro, Scilla, Katherine A, Mehra, Ranee, Rolfo, Christian
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2019
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6677959/
https://ncbi.nlm.nih.gov/pubmed/31423342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000524
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars